Style | Citing Format |
---|---|
MLA | Irandoost E, et al.. "Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 396, no. 4, 2023, pp. 621-631. |
APA | Irandoost E, Najibi S, Talebbeigi S, Nassiri S (2023). Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(4), 621-631. |
Chicago | Irandoost E, Najibi S, Talebbeigi S, Nassiri S. "Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications." Naunyn-Schmiedeberg's Archives of Pharmacology 396, no. 4 (2023): 621-631. |
Harvard | Irandoost E et al. (2023) 'Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications', Naunyn-Schmiedeberg's Archives of Pharmacology, 396(4), pp. 621-631. |
Vancouver | Irandoost E, Najibi S, Talebbeigi S, Nassiri S. Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023;396(4):621-631. |
BibTex | @article{ author = {Irandoost E and Najibi S and Talebbeigi S and Nassiri S}, title = {Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications}, journal = {Naunyn-Schmiedeberg's Archives of Pharmacology}, volume = {396}, number = {4}, pages = {621-631}, year = {2023} } |
RIS | TY - JOUR AU - Irandoost E AU - Najibi S AU - Talebbeigi S AU - Nassiri S TI - Focus on the Role of Nlrp3 Inflammasome in the Pathology of Endometriosis: A Review on Molecular Mechanisms and Possible Medical Applications JO - Naunyn-Schmiedeberg's Archives of Pharmacology VL - 396 IS - 4 SP - 621 EP - 631 PY - 2023 ER - |